This webinar will present new chemically modified oligonucleotide tools with the potential to tackle multifactorial disorders (among them, cancer and related drug resistance issues), while overcoming the limitations of oligonucleotide therapeutics.
Among the different oligonucleotide tools that will be presented, special emphasis will be placed on novel multi-target nanostructures specifically designed to administer several oligonucleotide drugs in a single dose, each of them active against a different therapeutic target. In addition, their functionalization with accessory molecules, such as fluorophores and targeting peptides for monitoring their specific delivery to tumours, will also be discussed.
Tuesday, 5 December 2023, 17:00 CET
Presentation of new chemical modification approaches to: i) increase the resistance of oligonucleotide drugs to 3’-exonuclease degradation, ii) create novel robust siRNA prodrugs that can act as substrates for Dicer, and iii) combine multiple oligonucleotide drugs into one single structure that can be selectively cleaved by specific intracellular stimuli, such as endogenous enzymes.
Dr. Montserrat Terrazas
Associate Professor - Department of Inorganic and Organic Chemistry (Organic Chemistry Section), Faculty of Chemistry, University of Barcelona, Barcelona, Spain
Dr. Martial Piotto
Pharma product manager of Biologics solutions